Background
Lung transplantation (LTx) is now a very established treatment for patients with end-stage lung diseases. However, shortage of suitable donors is still a major limitation for realizing the full success of this therapy. Donor lungs from both brain death donors (BDD) and circulatory death donors (DCD) are often injured as a result of brain injury-related cytokine storm, aspiration, infection, fluid overload, ventilator-associated lung injury, and warm ischemia, which prevents them safely being used for transplantation [1] . Attempts to transplant injured donor lungs can lead to high incidence of severe primary graft dysfunction (PGD) and associated short-and long-term consequences to recipients [2] . Therefore, utilization rates of lungs from multi-organ donors is low, ranging from 5% to 20%.
One of the most attractive strategies to increase donor lung utilization is by improving assessment and treatment of the organ once it is removed from the hostile peri-procurement environment of the donor. In order to achieve this, normothermic ex vivo lung perfusion (EVLP) has been developed over the last 10 years. The first use of EVLP in the more recent era was described by Steen to evaluate function of a DCD with subsequent transplantation [3] . The major contribution by this group was the development of a specific lung perfusion solution (Steen solution, Xvivo perfusion, Sweden) which allows perfusion of the organ without development of pulmonary edema. However, the technique described by Steen was limited in that it only allowed short-term (60 min) assessment of the lungs without allowing sufficient time for prolonged organ testing, treatment, and repair. In order to achieve these goals, the Toronto group developed an EVLP methodology that allowed stable lung perfusion and ventilation for 12 h with maintained physiologic stability [4, 5] . After extensive additional preclinical studies, this group performed the first clinical trial using EVLP to assess and improve high-risk donor lungs with subsequent transplantation [6] . Since then other clinical studies have been performed using different EVLP methods and different devices for both standard criteria lungs and high-risk donor lungs [7] [8] [9] [10] . Currently, most of the lung transplant community believes that EVLP is a very important tool to assess, treat, and recover injured organs, while there is significant skepticism about using this relatively expensive technology for standard criteria organs which normally do well with standard cold static preservation (CSP). Two randomized trials using standard criteria donors with EVLP have demonstrated the safety of the approach but no convincing superiority of EVLP vs. CSP [7, 11] . EVLP indications can be divided in four major categories: (1) high-risk donor lungs from BDD, (2) standard DCDs, (3) high-risk DCDs, (4) logistics (prolongation of preservation time). 4 . Logistics: EVLP can be a powerful tool to extend preservation times from the traditional 6-10 h to more than 20 h of total preservation time. Experimental and clinical studies have demonstrated the safety of this approach which has the potential to bring lung transplantation practice to a more semielective fashion with multiple benefits for patients and transplant teams [15] .
EVLP assessment
One key aspect of EVLP is the determination of organ suitability and what parameters one should rely on to deem if the organ is in good quality for transplantation. For most experts on this method, it is clear that evaluation of organ function should be done for several hours (minimum 3 h) before the final decision can be made. As lung injury in EVLP is reflected by development of pulmonary edema, lung compliance seems to be the most reliable method to detect early injury. Adjunct parameters such as airway pressures, vascular resistance, gas exchange function, bronchoscopy findings, X-ray images, and direct palpation of the lungs should be evaluated, and stable or improving trends are required for safe lung utilization. Perfusate biomarkers and new technology to measure extravascular lung water are being developed to further refine EVLP assessment for safe transplantation.
EVLP technology and models
Several industries have now been involved in developing machines for EVLP; however, the two more commonly used commercial devices are the XPS system from Xvivo Perfusion and the Organ Care System (OCS) system from Transmedics. The differences between the most used EVLP methods are described in Table 1 . In Toronto, where the single largest experience with EVLP exists, as well as in some European and South American countries, EVLP is performed using off the shelf ECMO-type components and a dome and cannulas from Xvivo and acellular perfusion with Steen Solution. While the model of EVLP provision has been largely used by centers performing EVLP in their own hospitals, more recently an "out of hospital" centralized lung repair center model has been proposed. The Lung Bioengineering (United Therapeutics) center located in Maryland (USA) is actively providing EVLP services to several American centers with a marked growth of activities over the last 2 years.
Conclusions
EVLP has been in clinical practice now for 10 years and it has safely increased lung transplantation activities. While the major benefit of this technology to date has been the ability to test the quality of questionable organs prior to LTx, the major impact should occur in the next few years by implementing more sophisticated organ repair strategies using drugs and biological agents such as gene or cell-based therapies.
